T cells that recognize HER2 teceptor may prevent HER2+ breast cancer recurrence

Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system -- a weakness that in principle could be corrected with a HER2-targeted vaccine -- according to a new study.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1Py9iwj